Samsung Galaxy S24 Boosts Sales, Reaches Four-Year High in Q1 2024 Smartphone Market 
South Korea Backs Naver in Business Rift with Japan Over Line App 
BYD Europe Challenges Tesla, EU Giants; Stellantis Defends Italian Turf 
PUMA Unveils 'Be You' Edition of the MB.03 Before Launching LaMelo Ball's Newest MB.04 Sneaker 
Target Adjusts LGBTQ Pride Month Merchandise Strategy Amid Backlash 
Honda Motor Posts 6-Fold Increase in 4Q Operating Profit of $1.96 Billion 
SEC Opens Investigation into Boeing Co. over Safety Statements 
Sriracha Shortage Predicted as Huy Fong Foods Stops Production of Famous Chili Sauce 
McDonald’s Sets Up Digital Marketing Fund to Introduce New Ordering Channels, Loyalty Program 
Kith and ASICS Gear Up for an Exclusive Sneaker Launch Inspired by South Korea 
OpenAI Set to Unveil Google Rival Search Tool Next Monday, Sources Reveal 
Tesla Cybertruck Warranty Woes: Owner Shocked as Coolant Leak Not Covered After 35 Miles 
Novavax, Sanofi Ink Deal to Commercialize COVID-19 Vaccine to Jointly Produce Combination Shots 
Coca-Cola Named New President of Its Namesake Foundation 
PepsiCo Aims to Make Its Spain Plant the First Facility to Reach Net-Zero Emissions 
Samsung Follows Apple, Abandons Autonomous Driving and EV Research Initiatives 
 - EconoTimes)
NEW ORLEANS, Feb. 10, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until April 4, 2017 to file lead plaintiff applications in a securities class action lawsuit against Stemline Therapeutics, Inc. (Nasdaq:STML), if they purchased the Company’s securities pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017 and/or between the expanded period of January 6, 2017 and February 1, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of Stemline and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 4, 2017.
About the Lawsuit
Stemline and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017, immediately prior to the Company’s secondary offering; and (ii) Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
